Mechanisms of resistance to antifungal therapy;Mecanismos de resistencia a la terapéutica antifúngica

Medicina Clinica

Volumn 126, Issue SUPPL.1, 2006, Pages 56-60

  Pontón, José ^a   Quindós, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antifungal agents; Azoles; Echinocandins; Mechanisms; Polyenes; Resistance

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; NYSTATIN; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BLOOD CULTURE; ENVIRONMENTAL CHANGE; FUNGUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; MYCOSIS; OROPHARYNX CANDIDIASIS; PLASTICITY; PREVALENCE; REVIEW; TREATMENT FAILURE;

EID: 34548588761     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13097528     Document Type: Article

References (34)

1. García Ruíz JC, Pontón J. Infecciones fúngicas invasivas en pacientes con hemopatías malignas: una aproximación clínica. Med Clin (Barc). 2000;115:305-12.
2. García Ruíz JC, Amutio E, Pontón J. Infección fúngica invasora en pacientes inmunodeficientes. Rev Iberoam Micol. 2004;21:55-62.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7.
4. Lumbreras C, Gavaldá J. Aspergilosis invasora: manifestaciones clínicas y tratamiento. Rev Iberoam Micol. 2003;20:79-89.
5. Masia M, Gutiérrez F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002;2:550-63.
6. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17.
7. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis. 1997;24:28-34.
8. Aguirre JM. Candidiasis orales. Rev Iberoam Micol. 2002;19:17-21.
9. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. 1997;25:843-6.
10. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;27:1291-4.
11. Spinillo A, Nicola S, Colonna L, Marangoni E, Cavanna C, Michelone G. Frequency and significance of drug resistance in vulvovaginal candidiasis. Gynecol Obstet Invest. 1994;38:130-3.
12. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994;38:1422-7.
13. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20:121-36.
14. Develoux M. Griseofulvin. Ann Dermatol Venereol. 2001;128:1317-25.
15. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans - Frequency of occurrence and antifungal susceptibility in the Scope program. Diag Microbiol Infect Dis. 1998;31:327-32.
16. Barchiesi F, Arzeni D, Caselli F, Scalise G. Primary resistance to flucytosine among clinical isolates of Candida spp. J Antimicrob Chemother. 2000;45:408-9.
17. Fasoli MO, Kerridge D, Morris PG, Torosantucci A. 19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism. Antimicrob Agents Chemother. 1990;34:1996-2006.
18. Quindós G, Ruesga MT, Martín-Mazuelos E, Salesa R, Alonso-Vargas R, Carrillo-Muñoz AJ, et al. In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol. 2004;21:63-9.
19. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, et al. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother. 1997;41:196-9.
20. Dick JD, Merz WG, Saral R. Incidence of polyene resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18:158-63.
21. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis. 1986;154:76-83.
22. Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta. 2002;1587:240-8.
23. Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol. 2002;5:379-85.
24. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001;45:2676-84.
25. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2:73-85.
26. Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindós G, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004;53:74-80.
27. Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol. 1989;14:98-100.
28. Klobucnikova V, Kohut P, Leber R, Fuchsbichler S, Schweighofer N, Turnowsky F, et al. Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the ERG1 gene. Biochem Biophys Res Comun. 2003;309:666-71.
29. Arévalo MP, Carrillo-Muñoz AJ, Salgado J, Cárdenes D, Brió S, Estivill D, et al. Antifungal activity of the echinocandin Anidulafungin (VER002-6, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother. 2003;51:163-6.
30. Carrillo-Muñoz AJ, Quindós G, Lopez-Ribot JL. Current developments in antifungal agents. Curr Med Chem-Anti-Infective Agents. 2004;3:297-323.
31. Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D glucan synthase inhibitors. Antimicrob Agents Chemother. 1997;41:2471-9.
32. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11:272-9.
33. Hospenthal DR, Murraya CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis. 2004;48:153-60.
34. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359:1135-44.